Compositions and methods for identifying depressive disorders

• US 10,457,991 B2
• Filed: 10/06/2017
• Issued: 10/29/2019
• Est. Priority Date: 01/17/2014
• Status: Active Grant

• Current Assignee: Northwestern University
• Original Assignee: Northwestern University
• Inventors: Redei, Eva E.
• Primary Examiner(s): Haney, Amanda
• Application Number:
  US15/727,186
• Publication Number:
  US 20180073079A1
• Time in Patent Office: 753 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

Provided herein are compositions, kits, and methods for the identification of depressive disorders. In particular, provided herein are compositions, kits, and methods for the detection or diagnosis of major depressive disorder.

Claims

1. A panel of biomarkers consisting of an isolated set of 100 or fewer full-length cDNA biomarkers, wherein said isolated set includes DAG1 , CTSB, and TMCC2 full-length cDNA biomarkers.

2. The panel of claim 1, further comprising one or more of RAPH1, MARCKS, ATP11C, CAST, IL13RA1, ADIPOR1, DENND5A, and GLRX5 full-length cDNA biomarkers.

3. The panel of claim 2, comprising three or more of RAPH1, MARCKS, ATP11C, CAST, IL13RA1, ADIPOR1, DENND5A, and GLRX5 full-length cDNA biomarkers.

4. The panel of claim 1, further comprising one or more of ADCY3, DGKA, FAM46A, IGSF4A/CADM1, KIAA1539, PSME1, and TLR7 full-length cDNA biomarkers.

5. The panel of claim 4, comprising three or more of ADCY3, DGKA, FAM46A, IGSF4A/CADM1, KIAA1539, PSME1, and TLR7 full-length cDNA biomarkers.